Protara Therapeutics, Inc. (TARA)
- Previous Close
3.5000 - Open
3.5250 - Bid 2.5200 x 200
- Ask 4.4100 x 200
- Day's Range
3.4100 - 3.6000 - 52 Week Range
1.5950 - 10.4800 - Volume
409,871 - Avg. Volume
347,785 - Market Cap (intraday)
133.483M - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1700 - Earnings Date May 1, 2025 - May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.00
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
www.protaratx.comRecent News: TARA
View More
Performance Overview: TARA
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TARA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TARA
View MoreValuation Measures
Market Cap
135.03M
Enterprise Value
-30.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.59%
Return on Equity (ttm)
-37.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-44.6M
Diluted EPS (ttm)
-2.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
170.29M
Total Debt/Equity (mrq)
2.68%
Levered Free Cash Flow (ttm)
-20.39M